Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report

Annals of Oncology

Volumn 10, Issue 5, 1999, Pages 561-567

  Fetscher, S R ^a   Brugger, W ^b   Engelhardt, R ^c   Kanz, L ^b   Hasse, J ^c   Frommhold, H ^a   Lange, W ^c   Mertelsmann, R ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NONE

Author keywords

Chemotherapy; Hematopoietic growth factor support; High dose chemotherapy; Peripheral blood stem cell transplantation; Small cell lung cancer; Treatment toxicity and mortality

Indexed keywords

CARBOPLATIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

EID: 0033053286     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026453922931     Document Type: Article

References (60)

1. Shepherd FA. The role of chemotherapy in the treatment of small-cell lung cancer. Chest Surg Clin N Am 1997; 7 (1): 113-33.
2. Sculier JP, Paesmanns M, Bureau G et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol 1996; 14 (8): 2337-44.
3. Bonner JA, Eagan RT, Liengswangwong V et al. Long-term results of a phase I-II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small-cell lung cancer. Cancer 1995; 76 (3): 406-12.
4. Shea RA, Perkins P, Allen PK et al. Limited-stage small-cell lung cancer: Patient survival after combined chemotherapy and radiation therapy with and without treatment protocols. Radiology 1995; 197 (3): 859-62.
5. Healey EA, Abner A. Thoracic and cranial radiotherapy for limited-stage small-cell lung cancer. Chest 1995; 107 (Suppl 6): S249-54.
6. Tada T, Minakuchi K, Koda M et al. Limited-stage small-cell lung cancer: Local failure after chemotherapy and radiation therapy. Radiology 1998; 208 (2): 511-5.
7. Kumar P. The role of thoracic radiotherapy in the management of limited-stage small-cell lung cancer: Past, present, and future. Chest 1997; 112 (Suppl 4): S259-65.
8. Liengswangwong V, Bonner JA, Shaw EG et al. Prophylactic cranial irradiation in limited-stage small-cell lung cancer. Cancer 1995; 75 (6): 1302-9.
9. Ichinose Y, Hara N, Ohta M et al. Comparison between resected and irradiated small-cell lung cancer in patients in stages I through IIIA. Ann Thorac Surg 1992; 53 (1): 95-100.
10. Lad T, Piantadosi S, Thomas P et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of SCLC to combination chemotherapy. Chest 1994; 106 (Suppl 6): S320-3.
11. Liu X, Li X, Pang Y et al. The results of treatment in 100 patients with limited-stage small-cell lung cancer. Cancer 1993; 71 (2): 326-31.
12. Muller LC, Salzer GM, Huber H et al. Multimodal therapy of small-cell lung cancer in TNM stages I through IIIa. Ann Thorac Surg 1992; 54 (3): 493-7.
13. Shea RA, Perkins P, Allen PK et al. Limited-stage small-cell lung cancer: Patient survival after combined chemotherapy and radiation therapy with and without treatment protocols. Radiology 1995; 197 (3): 859-62.
14. Albain KS, Crowley JJ, Hutchins L et al. Predictors of survival following relapse or progression of small-cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 1993; 72 (4): 1184-91.
15. Ihde DC. Small-cell lung cancer. State-of-the-art therapy 1994. Chest 1995; 107 (Suppl 6): S243-8.
16. Lassen U, Osterlind Kell, Hansen M et al. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1.714 consecutive patients. J Clin Oncol 1995; 13: 1215-20.
17. Turrisi AT, Kyungmann K, Blum R et al. Twice daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340 (4): 265-71.
18. Johnson BE, Bridges JD, Sobczeck M el al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy compared and and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14 (3): 806-13.
19. Choi NC, Hernon JD II, Rosenmann J et al. Phase I study of the maximum tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998; 16 (11): 3528-37.
20. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small-cell lung carcinoma: A phase I study. Cancer 1998; 82 (5): 836-41.
21. Demetri GD. Institution Harvard Medical School, Boston. Impact of hematopoietic growth factors on the management of small-cell lung cancer. Chest 1993; 103 (Suppl 4): S427-32.
22. Ihde DC, Mushine J, Kramer B et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022-9.
23. Prendiville J, Radford J, Thatcher N et al. Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine and radiotherapy. J Clin Oncol 1991; 9: 1446-53.
24. Smith IE, Perren TS, Ashley SA et al. Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1990; 8: 899-906.
25. Wolff AC, Ettinger DS, Neuberg D et al. Phase II study of ifosfamide, carboplatin and oral etoposide chemotherapy for extensive disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995; 13:1615-22.
26. Woll PW, Hodgetts J, Lomax L et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulation factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-9.
27. Chouaid C, Bassinet L, Fuhrmann C et al. Routine use of colony-stimulating factors is not cost effective and dose not increase patient comfort in the treatment of small-cell lung cancer: An analyses using a Markov model. J Clin Oncol 1998; 16 (8): 2700-7.
28. Tjan-Heijinen VCG, Biesma B, Festen J, Splinter TAW et al. Enhancing myelotoxicity due to granulocyte colony-stimulating factor until 48 hours before next chemotherapy course in patients in patients with small-cell lung carcinoma. J Clin Oncol 1998; 16 (8): 2708-14.
29. de Crevoisier R, le Cesne A, le Chevalier T. Dose-effect of chemotherapy in bronchial small-cell cancer. Revue des Maladies Respiratoires 1997; 14 (4): 269-75.
30. Elias AD. Dose-intensive therapy for small-cell lung cancer. Chest 1998; 113 (Suppl 1): S101-6.
31. Klasa R, Murray N, Coldman A. Dose-intensity meta-analysis of chemotherapy regimens in small-cell lung cancer. J Clin Oncol 1991; 9: 499-511.
32. Schiller JH. Dose-intense chemotherapy for limited stage small-cell lung cancer: Does it have a role? Proc Am Soc Clin Oncol 1995; 1995 educational book: 20-4.
33. Thatcher N, Lee SM, Woll PJ et al. Dose intensity in small-cell lung cancer. Semin Oncol 1998; 25 (2, Suppl 4): 12-8; 45-8 (Discussion).
34. Bao YH. High-dose chemotherapy with autologous bone marrow rescue for small-cell lung cancer. Chinese J Oncol 1992; 13 (6): 452-5.
35. Elias AD, Ayash L, Skarin AT et al. High-dose combined alkylating agent therapy with autologous stem-cell support and chest radiotherapy for limited small-cell lung cancer. Chest 1993; 103 (Suppl 4): S433-5.
36. Elias A. Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol 1997; 40 (Suppl): S64-9.
37. Humblet Y, Bosquee L, Weynants P, Symann M. High-dose chemo-radiotherapy cycles for LD small-cell lung cancer patients using G-CSF and blood stem cells. BMT 1996; 18 (Suppl 1): S36-9.
38. Ihde E, Deisseroth A, Lichter A et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 1986; 4: 1443-51.
39. Lazarus HM, Elias AD. Autologous bone marrow and peripheral progenitor cell transplants in small-cell lung cancer. BMT 1996; 17: 1-3.
40. Perey L, Rosti G, Lange A et al. Sequential high-dose ICE chemotherapy with circulating progenitor cells in small-cell lung cancer: An EBMT study. BMT 1996; 18 (Suppl 1): S40-3.
41. Pettengell R, Woll PJ, Thatcher N et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13 (1): 148-56.
42. Rushing DA, Friedenberg WR, Baldauf MC et al. High-dose carmustine and autologous bone marrow infusion in the treatment oft refractory or relapsed small-cell lung carcinoma. Cancer 1991; 68 (4): 720-4.
43. Sculier JP, Klastersky J, Stryckmans P et al. Late intensification in small-cell lung cancer: A phase I study of high-doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. J Clin Oncol 1985; 3: 184-91.
44. Shimizu E, Takaue Y, Yamamoto A et al. Patient with extensive small-cell lung cancer given moderately dose-intensified chemotherapy and peripheral blood stem-cell support. Jap J Clin Oncol 1995; 25 (5): 213-7.
45. Smith I, Evans B, Harland S et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in treatment of small-cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14: 120-7.
46. Souhami R, Hajichristou H, Miles D et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 1989; 24: 321-5.
47. Spitzer G, Farha P, Valdivieso M et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4: 4-12.
48. Stewart P, Buckner C, Thomas E et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell carcinoma of the lung. Cancer Treat Rep 1983; 67: 1055-62.
49. Tomeczko J, Pacuszko T, Napora P, Lange A. Treatment intensification which includes high-dose induction improves survival of lung carcinoma patients treated by high-dose chemotherapy with hematopoietic progenitor cell rescue but does not prevent high rate of relapses. BMT 1996; 18 (Suppl 1): S44-7.
50. Basade MM, Gulati SC. High-dose chemotherapy with autologous bone marrow/stem-cell rescue in lung cancer. Lancet 1996; 347 (9005): 847-8.
51. Lazarus HM, Elias AD. Autologous bone marrow and peripheral blood progenitor cell transplants in small-cell lung cancer. BMT 1996; 17(1): 1-3.
52. Tiefengraber E, Sebesta C, Kier P et al. Possible role of autotransplantation in small-cell bronchial carcinoma. Wiener Medizinische Wochenschrift 1995; 145 (2-3): 50-2.
53. Fetscher S, Brugger W, Engelhardt R et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol 1997; 8: 49-56.
54. Brugger W, Fetscher S, Hasse J et al. Multimodality-treatment including high-dose chemotherapy with peripheral blood stem-cell transplantation in limited-disease small-cell lung cancer. Semin Oncology 1998; 25: 42-8.
55. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-61.
56. Fetscher S, Lübbert M, Waller CF et al. Early onset of secondary chronic myelogenous leukemia after after high-dose chemotherapy and autologous hematopoietic stem-cell transplantation for small-cell lung cancer. Blood 1997; 90 (Supplement 1 (2)): 276b (Abstr 3989).
57. Johnson BE, Ihde DE, Matthews MJ et al. Non-small-cell lung cancer, major cause of late mortality in patients with small-cell lung cancer. Am J Med 1996; 80: 1103-10.
58. Bhatia S, Ramsay NKC, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87 (9): 3633-9.
59. Ghaemmaghami M, Jett R. New agents in the treatment of small-cell lung cancer. Chest 1998; 113 (Suppl 1): S86-91.
60. Kalemkerian GP, Jiroutek M, Ettinger DS et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in extensive stage small-cell lung carcinoma: An ECOG study. Cancer 1998; 83(6): 1102-8.